1. Is the intrinsic sympathomimetic activity (ISA) of beta-blocking compounds relevant in acute myocardial infarction?

   • B. Silke
   • S. P. Verma
   • S. H. Taylor

   Originals Pages: 509 - 515

2. Influence of cardioselectivity and respiratory disease on pulmonary responsiveness to beta-blockade

   • H. W. Clague
   • D. Ahmad
   • S. G. Carruthers

   Originals Pages: 517 - 523

3. Changes in left ventricular mass during a double-blind study with chlorthalidone and slow-release nifedipine

   • L. A. Ferrara
   • G. de Simone
   • G. Vallone

   Originals Pages: 525 - 528

4. Double-blind comparison of once-daily bopindolol, pindolol and atenolol in essential hypertension

   • W. Schiess
   • D. Welzel
   • R. Gugler

   Originals Pages: 529 - 534

5. Effect on heart rate over 24 hours of pindolol administered for 14 days

   • J. P. Kantelip
   • J. F. Trolese
   • P. Duchêne-Marullaz

   Originals Pages: 535 - 538

6. Dose-response relationship in normal subjects of prenalterol, a beta-adrenergic agonist with positive inotropic and resistance lowering effects

   • S. Rasmussen
   • P. -F. Høilund-Carlsen
   • J. Giese

   Originals Pages: 539 - 543

7. Simple and reliable radioreceptor assay for beta-adrenoceptor antagonists and active metabolites in native human plasma

   • A. Wellstein
   • D. Palm
   • E. Mutschler

   Originals Pages: 545 - 553

8. Hydralazine-induced lupus: is there a toxic metabolic pathway?

   • J. A. Timbrell
   • V. Facchini
   • R. Mansilla-Tinoco

   Originals Pages: 555 - 559

9. Studies on the possible central effects in man of a neuropeptide (ACTH 4–9 analogue)

   • A. N. Nicholson
   • B. M. Stone
   • S. J. Jones

   Originals Pages: 561 - 565

10. Physical exercise and binding of digoxin to skeletal muscle — Effect of muscle activation frequency

    • T. Joreteg
    • T. Jogestrand

    Originals Pages: 567 - 570

11. Quinidine-induced changes in serum and skeletal muscle digoxin concentration; evidence of saturable binding of digoxin to skeletal muscle

    • T. Jogestrand
    • K. Schenck-Gustafsson
    • R. Dahlqvist

    Originals Pages: 571 - 575

12. Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (HOE 498) in healthy subjects

    • P. U. Witte
    • R. Irmisch
    • H. Metzger

    Originals Pages: 577 - 581

13. Pharmacokinetics of propranolol during pregnancy

    • M. F. O'Hare
    • C. D. Kinney
    • D. G. McDevitt

    Originals Pages: 583 - 587

14. Pharmacokinetics of high doses of piretanide in moderate to severe renal failure

    • C. Marone
    • F. C. Reubi
    • W. Lahn

    Originals Pages: 589 - 593

15. Implications of intraindividual variability in bioavailability studies of furosemide

    • A. Grahnén
    • M. Hammarlund
    • T. Lundqvist

    Originals Pages: 595 - 602

16. Use of single doses and rapid sampling to detect interactions with cimetidine

    • H. Ghabrial
    • P. J. Harman
    • K. J. Breen

    Originals Pages: 603 - 606

17. Pharmacokinetics of methotrexate in erythrocytes in psoriasis

    • J. Hendel
    • A. Nyfors

    Originals Pages: 607 - 610

18. Presence of chlorprothixene and its metabolites in breast milk

    • I. Matheson
    • A. Evang
    • G. Syversen

    Short Communication Pages: 611 - 613

19. Pharmacokinetics of the oral narcotic analgesic bezitramide and preliminary observations on its effect on experimentally induced pain

    • D. K. F. Meijer
    • G. Hovinga
    • H. Wesseling

    Short Communication Pages: 615 - 618

20. Biperiden effects and plasma levels in volunteers

    • M. Hollmann
    • E. Brode
    • N. Wetzelsberger

    Short Communication Pages: 619 - 621

21. Cimetidine bioavailability and variable renal clearance

    • A. Grahnén

    Letter To The Editor Pages: 623 - 624

22. Announcements

    Announcement Pages: 625 - 625